Voclosporin with mycophenolic acid and low-dose steroids in combination with the treatment of lupus nephritis key 3-phase bed trial struck positive results

recently, Aurinia Pharmaceuticals(http://announced that the company's development of voclosporin, in combination with mycophenolic acid (MM) and low-dose steroids, reached all major and critical secondary endpoints in the critical Phase 3 clinicaltrial(http://for patients with lupus nephritis (LN)significantly improves kidney remission in patients compared to standard therapiesVoclosporinVoclosporin is a potential "best-in-class" calcium-to-sympathetic neurophosphatase inhibitor (CNI)By inhibiting calcium-toned neurophosphatase, it blocks IL-2 expression and T-cell-mediated immune responses and stabilizes foot cells (podocyte) in the kidneysVoclosporin was granted fast-track eligibility by theFDA(http://in 2016The global study, involving 357 LN patients, showed that voclosporin achieved a renal respo
nse rate of 40.8 percent,compared with 22.5 percent (p0.00 http://
1 ) in the control group 　　Aurinia plans to submit an application for New Drug (http:// in the first half of next year, and we look forward to the early approval of this innovative therapy for the benefit of LN patients